{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:36:21Z","timestamp":1771493781177,"version":"3.50.1"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To characterize the indication, outcomes, and adverse effects of rituximab (RTX) treatment in a large single-center cohort of patients with systemic rheumatoid vasculitis (RV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We retrospectively reviewed the medical charts of 17 patients treated with RTX for systemic RV from 2000 to 2017. Clinical characteristics, outcomes, and adverse effects were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>At RV diagnosis, mean age was 59 years, 59% were female, 94% were white, and 82% had positive rheumatoid factor. At the time of initiating RTX, median Birmingham Vasculitis Activity Score for rheumatoid arthritis was 4.0 (interquartile range 2.0\u20137.5). RV presented in the skin in 8 patients (47%), as mononeuritis multiplex in 2 (12%), inflammatory ocular disease in 2 (12%), and affected multiple organ systems in 5 (29%). RTX was used for induction therapy in 8 patients (47%), relapsing RV in 4 (24%), second-line therapy in 2 (12%), and salvage therapy or in combination with another agent in 3 (18%). At 3 months, 2 (13%) of 15 patients with available followup information achieved complete remission (CR), and 10 (67%) achieved partial response (PR). At 6 months, 6 patients (40%) achieved CR, 8 (53%) achieved PR, and one had no response. At 12 months, 8 of 13 patients with available records (62%) had CR and 5 patients (38%) had PR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Systemic RV is difficult to treat effectively. CR of RV was achieved in 62% and PR in 38% of patients within 12 months of RTX use. Further evidence is needed to inform treatment for patients with RV.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.181397","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T16:25:16Z","timestamp":1560615916000},"page":"518-523","source":"Crossref","is-referenced-by-count":18,"title":["Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-4038","authenticated-orcid":false,"given":"Caitrin M.","family":"Coffey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7475","authenticated-orcid":false,"given":"Cynthia S.","family":"Crowson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Ytterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-898X","authenticated-orcid":false,"given":"Ashima","family":"Makol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"2021110311500899000_47.4.518.1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000126"},{"key":"2021110311500899000_47.4.518.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket475"},{"key":"2021110311500899000_47.4.518.3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90654-5"},{"key":"2021110311500899000_47.4.518.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket326"},{"key":"2021110311500899000_47.4.518.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"2021110311500899000_47.4.518.6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/acr.20689","article-title":"Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab registry","volume":"64","author":"Puechal","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2021110311500899000_47.4.518.7","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2021110311500899000_47.4.518.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"2021110311500899000_47.4.518.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"2021110311500899000_47.4.518.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279"},{"key":"2021110311500899000_47.4.518.11","unstructured":"Birmingham Vasculitis Activity Score (version 3). [Internet. Accessed October 3, 2019.] Available from: golem.ndorms.ox.ac.uk\/calculators\/bvas.html"},{"key":"2021110311500899000_47.4.518.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken129"},{"key":"2021110311500899000_47.4.518.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel318"},{"issue":"Suppl 57","key":"2021110311500899000_47.4.518.14","first-page":"S81","article-title":"Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers","volume":"28","author":"Assmann","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2021110311500899000_47.4.518.15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-010-0130-1","article-title":"Rheumatoid vasculitis: vanishing menace or target for new treatments?","volume":"12","author":"Bartels","year":"2010","journal-title":"Curr Rheumatol Rep"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.181397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:51:49Z","timestamp":1635965509000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.181397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.3899\/jrheum.181397"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.181397","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}